Many attributes of API particles (e.g., size, density, morphology, hydroscopicity, static behavior, etc.) can impact the quality of a final drug product. It is ideal to obtain the desired particle attribute(s) through well-designed and controlled crystallization process.

•  Obtain Desired Product PSD

　Proper engineering and application of technologies enable our processes to deliver products with targeted particle size

    distribution (PSD).

•  Engineer Crystal Morphology

　For systems giving undesired crystal morphologies, we develop processes with improved morphology for either product

    quality or processing efficiency.

Crystal Pharmatech is the first technology-driven, China based contract research organization (CRO) that focuses on materials science and engineering for drug development. We partner with clients to ensure comprehensive solutions for their needs in solid-state research, crystallization process development, and preformulation studies. We guide clients in the discovery and selection of the optimal solid phase for drug development using all aspects of pre-formulation studies, including API process and formulation development, regulatory support and intellectual property protection.

Founded in 2010, Crystal Pharmatech has business relationships with over 60 global pharmaceutical companies. High quality service, a culture of confidentiality, and fast turnaround with cost-effective pricing are our trademarks. As we continue to grow, Crystal Pharmatech will always keep customers our number one priority. We will also continue to be at the forefront of innovation in the field of solid-state chemistry so that our customers can reap the benefits of key discoveries in an ever changing field.

Our Scientific Advisory Board includes global leaders in drug development covering amorphous dispersions, co-crystals, crystallization, solid forms, formulation and pre-formulation. The role of our board is all encompassing while we search for new scientific areas for internal and external projects.